We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novo Nordisk (NVO) Increases Yet Falls Behind Market: What Investors Need to Know
Read MoreHide Full Article
Novo Nordisk (NVO - Free Report) ended the recent trading session at $37.61, demonstrating a +1.9% change from the preceding day's closing price. This move lagged the S&P 500's daily gain of 2.51%. Meanwhile, the Dow gained 2.85%, and the Nasdaq, a tech-heavy index, added 2.8%.
Prior to today's trading, shares of the drugmaker had lost 4.67% was narrower than the Medical sector's loss of 5.12% and lagged the S&P 500's loss of 1.66%.
Market participants will be closely following the financial results of Novo Nordisk in its upcoming release. The company's upcoming EPS is projected at $0.87, signifying a 5.43% drop compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $11.13 billion, indicating a 1.08% growth compared to the corresponding quarter of the prior year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.37 per share and a revenue of $45.22 billion, signifying shifts of -14.9% and -3.32%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for Novo Nordisk. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 2.51% higher within the past month. Novo Nordisk is currently sporting a Zacks Rank of #3 (Hold).
Looking at valuation, Novo Nordisk is presently trading at a Forward P/E ratio of 10.97. This valuation marks a discount compared to its industry average Forward P/E of 14.2.
Also, we should mention that NVO has a PEG ratio of 8.7. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.31 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 155, this industry ranks in the bottom 37% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Novo Nordisk (NVO) Increases Yet Falls Behind Market: What Investors Need to Know
Novo Nordisk (NVO - Free Report) ended the recent trading session at $37.61, demonstrating a +1.9% change from the preceding day's closing price. This move lagged the S&P 500's daily gain of 2.51%. Meanwhile, the Dow gained 2.85%, and the Nasdaq, a tech-heavy index, added 2.8%.
Prior to today's trading, shares of the drugmaker had lost 4.67% was narrower than the Medical sector's loss of 5.12% and lagged the S&P 500's loss of 1.66%.
Market participants will be closely following the financial results of Novo Nordisk in its upcoming release. The company's upcoming EPS is projected at $0.87, signifying a 5.43% drop compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $11.13 billion, indicating a 1.08% growth compared to the corresponding quarter of the prior year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.37 per share and a revenue of $45.22 billion, signifying shifts of -14.9% and -3.32%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for Novo Nordisk. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 2.51% higher within the past month. Novo Nordisk is currently sporting a Zacks Rank of #3 (Hold).
Looking at valuation, Novo Nordisk is presently trading at a Forward P/E ratio of 10.97. This valuation marks a discount compared to its industry average Forward P/E of 14.2.
Also, we should mention that NVO has a PEG ratio of 8.7. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.31 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 155, this industry ranks in the bottom 37% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.